Investors Menu
Tilray Acquires Majority Position in Amended MedMen Convertible Notes
Investment Provides Tilray a Potential Accelerated Path into U.S. Cannabis Market Upon Federal Legalization Amendment and Extension of Convertible Notes Enables MedMen to Reshape Balance Sheet and Further Accelerate its Growth Trajectory Tilray and MedMen CEOs to Host a Conference Call and Webcast
August 17, 2021
Tilray Launches New Medical Cannabis Edibles in Canada
New Product Innovations Respond to Patient Needs Across Medical Category NEW YORK & LEAMINGTON, Ontario --(BUSINESS WIRE)--Aug. 5, 2021-- Tilray, Inc. (“ Tilray”) (Nasdaq I TSX: TLRY), a global pioneer in medical cannabis research, cultivation, and production, today announced the launch of medical
August 5, 2021
Tilray, Inc. Reports 2021 Fiscal Year and Fourth Quarter Results
Net Revenue Increased 27% to $513 Million Compared to Prior Year Net Income of $33.6 Million , Adjusted EBITDA of $12.3 Million , Net Cash from Operating Activities of $8.3 Million and Positive Free Cash Flow of $3.3 Million in Q4 Completed Business Combination with Aphria Inc., Achieved $35
July 28, 2021